JPMorgan Chase & Co. Cuts Pfizer (NYSE:PFE) Price Target to $28.00

Posted by ABMN Staff on Jul 11th, 2026

Pfizer (NYSE:PFE – Free Report) had its price target trimmed by JPMorgan Chase & Co. from $30.00 to $28.00 in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on PFE. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a report on Tuesday, June 9th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Finally, HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $32.00 to $28.00 in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.56.

Get Our Latest Stock Report on Pfizer

Pfizer Price Performance

Shares of NYSE PFE opened at $24.21 on Wednesday. Pfizer has a twelve month low of $23.11 and a twelve month high of $28.75. The firm has a fifty day simple moving average of $25.37 and a 200 day simple moving average of $26.18. The company has a market capitalization of $138.01 billion, a PE ratio of 18.48 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the prior year, the firm posted $0.92 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts forecast that Pfizer will post 2.97 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio is presently 131.30%.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently modified their holdings of the company. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. United Bank grew its holdings in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares during the last quarter. Sei Investments Co. increased its position in shares of Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC raised its holdings in shares of Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: The U.S. FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer, expanding the label for a key Pfizer/Astellas regimen and potentially opening the door to more sales in oncology. Article: U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Positive Sentiment: Pfizer’s oncology story also got incremental attention from a completed lorlatinib lung cancer study and other clinical updates, which keep investors focused on the company’s pipeline rather than only its mature products. Article: Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors
Neutral Sentiment: Bank of America lowered its price target on Pfizer to $26 from $27 while keeping a neutral rating, signaling limited upside but no major change in its overall stance. Article: Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00.
Negative Sentiment: Several market commentary pieces highlighted concerns about Pfizer’s growth outlook and mixed second-quarter expectations, including skepticism about how quickly Seagen-related benefits will show up in results. Article: Pfizer Poised for Mixed Second Quarter, RBC Says

About Pfizer

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.